SMi’s 10th annual Clinical Trials in CNS conference will be an ideal platform for leading industry experts to discover the current and future opportunities within the essential field of CNS drug development. This conference will address current clinical drug discovery activities, as well as innovative and effective drug development strategies and potential problems often faced in clinical trials.

This conference will focus on a wide range of therapeutic areas such as Multiple Sclerosis, Parkinson’s and Alzheimer’s, as well as considering a multitude of psychiatric disorders with in-depth discussions and case study presentations from the key industry players.

As such a fast-progressing and important field, it is vital that you are kept up to date with the latest developments and advances in CNS Clinical Trials, such as novel translational research studies. This conference will offer a unique opportunity for you to learn about the field from key opinion leaders and will present a fantastic platform for networking with senior executives from the pharmaceutical industry.

Key topics to be addressed:

• Cognition enhancement
• Latest developments in MS, PD and AD clinical development
• Biomarkers and CNS clinical trials
• Participant recruitment and retention issues in CNS clinical trials
• Schizophrenia and depression: specific considerations.
• Efficacy predictions
• Current challenges in translational CNS research
• Facilitating and establishing industry and academic partnering
• Early phase development trials in CNS

Speakers presenting at this year’s event include...

• Paul Thompson, Associate, Director Discovery Medicine Unit, GSK
• Hitendra Parmar, European Medical Director for Alzheimer’s Disease, Pfizer
• Georg Terstappen, Director and Department Head, Neuroscience Discover, Abbott
• Sophie Dix, Senior Research Scientist, Neurodegenerative Diseases Drug Hunting Team, Lilly
• Florien von Raison, Head of Global Clinical Development Unit, Parkinson’s Diseases, Merck Serono
• Chas Bountra, Chief Scientist, Structural Genomics Consortium, Univeristy of Oxford
• Simon Ridley, Head of Research, Alzheimer’s Research UK

Go to the programme: http://www.smi-online.co.uk/2011cnstrials9.asp

Alternatively contact Zain Philbey on +44 (0) 20 7827 6722 or e-mail: zphilbey@smi-online.co.uk